U.S., March 24 -- ClinicalTrials.gov registry received information related to the study (NCT07488481) titled 'Renal Ex Vivo SYN002 Perfusion to Eliminate CMV Transmission' on March 12.
Brief Summary: Donor organs often carry latent Cytomegalovirus (CMV) infection that may be transmitted to the recipient. The goal of this clinical trial is to determine the safety of SYN002 treatment during Ex-Vivo Organ Perfusion (EVOP) in clinical kidney transplantation. Donor kidneys will be treated on the EVOP system with SYN002 in order to decrease the burden of latent CMV in the organ and mitigate the transmission of cytomegalovirus (CMV).
Study Start Date: March 16
Study Type: INTERVENTIONAL
Condition:
Cytomegalovirus (CMV) Infection
Kidney Transp...